219 related articles for article (PubMed ID: 26058994)
1. Drug-Drug Interactions of a Novel κ-Opioid Receptor Agonist, Nalfurafine Hydrochloride, Involving the P-Glycoprotein.
Ando A; Sasago S; Ohzone Y; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):549-58. PubMed ID: 26058994
[TBL] [Abstract][Full Text] [Related]
2. Identification of human cytochrome P450 enzymes involved in the metabolism of a novel к-opioid receptor agonist, nalfurafine hydrochloride.
Ando A; Oshida K; Fukuyama S; Watanabe A; Hashimoto H; Miyamoto Y
Biopharm Drug Dispos; 2012 Jul; 33(5):257-64. PubMed ID: 22581509
[TBL] [Abstract][Full Text] [Related]
3. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
4. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
[TBL] [Abstract][Full Text] [Related]
5. Essential structure of the κ opioid receptor agonist nalfurafine for binding to the κ receptor.
Nagase H; Fujii H
Curr Pharm Des; 2013; 19(42):7400-14. PubMed ID: 23448474
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
Umeuchi H; Kawashima Y; Aoki CA; Kurokawa T; Nakao K; Itoh M; Kikuchi K; Kato T; Okano K; Gershwin ME; Miyakawa H
Eur J Pharmacol; 2005 Aug; 518(2-3):133-9. PubMed ID: 16055114
[TBL] [Abstract][Full Text] [Related]
7. The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.
Nemoto T; Yamamoto N; Wada N; Harada Y; Tomatsu M; Ishihara M; Hirayama S; Iwai T; Fujii H; Nagase H
Bioorg Med Chem Lett; 2013 Jan; 23(1):268-72. PubMed ID: 23200250
[TBL] [Abstract][Full Text] [Related]
8. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
Miyamoto Y; Oh T; Aihara E; Ando A
Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
[TBL] [Abstract][Full Text] [Related]
9. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
Dunn A; Windisch K; Ben-Ezra A; Pikus P; Morochnik M; Erazo J; Reed B; Kreek MJ
Psychopharmacology (Berl); 2020 Aug; 237(8):2405-2418. PubMed ID: 32435819
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
13. The anthelminthic agent albendazole does not interact with p-glycoprotein.
Merino G; Alvarez AI; Prieto JG; Kim RB
Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
[TBL] [Abstract][Full Text] [Related]
15. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
16. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
[TBL] [Abstract][Full Text] [Related]
18. Topical administration of the kappa opioid receptor agonist nalfurafine suppresses corneal neovascularization and inflammation.
Shokirova H; Inomata T; Saitoh T; Zhu J; Fujio K; Okumura Y; Yanagawa A; Fujimoto K; Sung J; Eguchi A; Miura M; Nagino K; Hirosawa K; Kuwahara M; Akasaki Y; Nagase H; Murakami A
Sci Rep; 2021 Apr; 11(1):8647. PubMed ID: 33883646
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
20. Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice.
Zhang Y; Kreek MJ
Neuropharmacology; 2020 Oct; 176():108244. PubMed ID: 32702404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
